Eli Lilly and Company (NYSE:LLY) Shares Down 0.2% – Should You Sell?

Eli Lilly and Company (NYSE:LLY)’s share price traded down 0.2% during mid-day trading on Wednesday . The company traded as low as $780.30 and last traded at $787.82. 696,068 shares were traded during mid-day trading, a decline of 78% from the average session volume of 3,208,198 shares. The stock had previously closed at $789.32.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Guggenheim raised their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. BMO Capital Markets increased their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Finally, Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Stock Down 0.0 %

The firm’s fifty day simple moving average is $859.30 and its two-hundred day simple moving average is $870.41. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $749.13 billion, a price-to-earnings ratio of 85.17, a price-to-earnings-growth ratio of 2.86 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same period last year, the company earned $0.10 EPS. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is currently 56.22%.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.13% of the stock is owned by insiders.

Institutional Trading of Eli Lilly and Company

Hedge funds have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. lifted its stake in shares of Eli Lilly and Company by 357.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 11,074 shares of the company’s stock valued at $8,615,000 after purchasing an additional 8,651 shares in the last quarter. Coppell Advisory Solutions Corp. acquired a new stake in Eli Lilly and Company in the first quarter valued at $252,000. Semmax Financial Advisors Inc. increased its position in shares of Eli Lilly and Company by 89.2% in the 1st quarter. Semmax Financial Advisors Inc. now owns 157 shares of the company’s stock worth $119,000 after purchasing an additional 74 shares during the last quarter. XML Financial LLC grew its stake in Eli Lilly and Company by 17.4% in the first quarter. XML Financial LLC now owns 1,758 shares of the company’s stock worth $1,367,000 after purchasing an additional 261 shares in the last quarter. Finally, National Wealth Management Group LLC increased its holdings in Eli Lilly and Company by 163.6% in the first quarter. National Wealth Management Group LLC now owns 1,189 shares of the company’s stock valued at $925,000 after buying an additional 738 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.